NCT06345183View on ClinicalTrials.gov

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Active, not recruitingOBSERVATIONAL
Enrollment

327

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
Advanced Renal Cell Carcinoma (aRCC)
Interventions
COMBINATION_PRODUCT

Nivolumab + Ipilimumab combination therapy

As per product label

COMBINATION_PRODUCT

Pembrolizumab + Lenvatinib combination therapy

As per product label

Trial Locations (1)

43017

Cardinal Health, Dublin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06345183 - Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients | Biotech Hunter | Biotech Hunter